GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » Debt-to-Asset

Defence Therapeutics (XCNQ:DTC) Debt-to-Asset : 2.27 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics Debt-to-Asset?

Defence Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$1.49 Mil. Defence Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.02 Mil. Defence Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was C$0.67 Mil. Defence Therapeutics's debt to asset for the quarter that ended in Dec. 2023 was 2.26.


Defence Therapeutics Debt-to-Asset Historical Data

The historical data trend for Defence Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics Debt-to-Asset Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22
Debt-to-Asset
- - -

Defence Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3.85 0.52 1.03 2.27

Competitive Comparison of Defence Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Defence Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Defence Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Defence Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Defence Therapeutics's Debt-to-Asset falls into.



Defence Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Defence Therapeutics's Debt-to-Asset for the fiscal year that ended in Jun. 2022 is calculated as

Defence Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Defence Therapeutics  (XCNQ:DTC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Defence Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Defence Therapeutics (XCNQ:DTC) Business Description

Traded in Other Exchanges
Address
200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.
Executives
Sarkis Meterissian Director